January 2010

NEW YORK (Reuters Health) Jan 08 - Depot medroxyprogesterone is known to lower bone density, but women may be able to limit the loss by not smoking and getting even moderate amounts of calcium, a new study hints.

The findings, say researchers, show that not all women are at equal risk of bone loss from depot medroxyprogesterone (DMPA) -- better known by the brand-name Depo Provera.

From an Indian country advantage point of view, we must first understand that the opportunity for Indian biosimilar players is in four key growth segments on the basis of products, services, technology and applications.

When we say biosimilars, we tend to think about products and services segment, however, we seem to forget the applications and technologies. Some of the examples include:

Chugai Pharmaceutical Co, Ltd and F Hoffmann-La Roche Ltd announced that the United States (US) Food and Drug Administration (FDA) approved Actemra, the humanized anti-human IL-6 (interleukin-6) receptor monoclonal antibody (tocilizumab, RoACTEMRA in the European Union) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumour necrosis factor (TNF) antagonist therapies.

Reata Pharmaceuticals, Inc and Kyowa Hakko Kirin Co, Ltd they have entered into a licensing agreement that provides Kyowa Hakko Kirin with the exclusive rights to develop and commercialize Reata's lead compound, bardoxolone methyl (bardoxolone), in Japan and other selected Asian markets. Under the terms of the agreement, Reata is eligible to receive up to US$ 272 million in up-front fees and milestone payments, in addition to double-digit royalties.

Syllabus for GPAT Paper

Postgraduate admissions with MHRD scholarship

Naprod Lifesciences

Job as BUSINESS DEVELOPMENT MANAGER (CIS COUNTRIES) FOR PHARMA FORMULATIONS

Structure of GPAT 2010

Bonsai Pharma

Job in Quality Control